Evidence map›Paper›PMID 22363817›Full record

ArticlePloS one2012

Matrix-bound PAI-1 supports cell blebbing via RhoA/ROCK1 signaling.

Amandine Cartier-Michaud, Michel Malo, Cécile Charrière-Bertrand, Gilles Gadea, Christelle Anguille, Ajitha Supiramaniam, Annick Lesne, Franck Delaplace, Guillaume Hutzler, Pierre Roux and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Molecular biomarkers of Graves' ophthalmopathy.Experimental and molecular pathology · 2019
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Amandine Cartier-MichaudIBISC EA 4526, Evry Val d'Essonne University, Evry, France.
Michel Malo
Cécile Charrière-Bertrand
Gilles Gadea
Christelle Anguille
Ajitha Supiramaniam
Annick Lesne
Franck Delaplace
Guillaume Hutzler
Pierre Roux
Daniel A Lawrence
Georgia Barlovatz-Meimon
Université d'Évry Val-d'Essonne · FRCentre National de la Recherche Scientifique · FRInformatique, Biologie Intégrative et Systèmes Complexes · FRMichigan United · USUniversité de Montpellier · FR

Funding

Unraveling the role of tPA in the neurovascular unitR01HL055374 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David Antonetti, Daniel A Lawrence · 1995 to 2026
$8.6M
Mechanism of thrombolytic tPA induced intracerebral hemorrhage after strokeR01NS079639 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAWRENCE, DANIEL A · 2012 to 2016
$1.7M
NHLBI NIH HHS R01 HL055374NINDS NIH HHS R01 NS079639
6 · The paper itself

Abstract

The microenvironment of a tumor can influence both the morphology and the behavior of cancer cells which, in turn, can rapidly adapt to environmental changes. Increasing evidence points to the involvement of amoeboid cell migration and thus of cell blebbing in the metastatic process; however, the cues that promote amoeboid cell behavior in physiological and pathological conditions have not yet been clearly identified. Plasminogen Activator Inhibitor type-1 (PAI-1) is found in high amount in the microenvironment of aggressive tumors and is considered as an independent marker of bad prognosis. Here we show by immunoblotting, activity assay and immunofluorescence that, in SW620 human colorectal cancer cells, matrix-associated PAI-1 plays a role in the cell behavior needed for amoeboid migration by maintaining cell blebbing, localizing PDK1 and ROCK1 at the cell membrane and maintaining the RhoA/ROCK1/MLC-P pathway activation. The results obtained by modeling PAI-1 deposition around tumors indicate that matrix-bound PAI-1 is heterogeneously distributed at the tumor periphery and that, at certain spots, the elevated concentrations of matrix-bound PAI-1 needed for cancer cells to undergo the mesenchymal-amoeboid transition can be observed. Matrix-bound PAI-1, as a matricellular protein, could thus represent one of the physiopathological requirements to support metastatic formation.

Indexed as

Cell Line, TumorCell MovementCell Surface ExtensionsComputer SimulationEnzyme ActivationExtracellular MatrixHumansImmobilized ProteinsMesodermModels, BiologicalPlasminogen Activator Inhibitor 1Protein BindingrhoA GTP-Binding Proteinrho-Associated KinasesSignal TransductionUrokinase-Type Plasminogen ActivatorImmobilized ProteinsPlasminogen Activator Inhibitor 1rhoA GTP-Binding Proteinrho-Associated KinasesROCK1 protein, humanUrokinase-Type Plasminogen Activator

Identifiers

PMID22363817
PMCPMC3283740
OpenAlexW2027560643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.